


## *Dishman Falls 18% in Eight Trades on Weak Q3 Earnings*

Shares of Dishman Pharmaceuticals have fallen almost 18% in the past eight days, after the company's October-December quarter results fell below analysts' expectations. Analysts attributed the disappointing earnings to weak performance by the company's Swiss arm Carbogen Amcis. In a recent conference call, the management assured analysts that Carbogen will announce a 'major restructuring' exercise soon to save costs and boost profitability. An analyst, who tracks the company, said investors would adopt a wait and watch approach for



some time as the impact of the restructuring on the company's profitability will be seen only in 2012-13. The stock fell 5.5% to ₹91.9 against a 0.8% fall in the Sensex on Tuesday.

Industry